Real Time Amplitude Spectrum Area to Guide Defibrillation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

31 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-04-28

Study Completion Date

2021-07-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

AMSA trial is a multicenter, randomized, controlled study in out-of-hospital cardiac arrest patients.

The purpose of the study is to test the hypothesis that a real time AMSA analysis during CPR may predict the success of defibrillation and optimize the timing of defibrillation delivery.

The primary end-point is the efficacy of the AMSA-CPR: termination of VF/VT with achievement of ROSC for an AMSA ≥ 15.5 mV-Hz

All patients meeting inclusion/exclusion criteria and receiving cardiopulmonary resuscitation are randomized into two groups: AMSA-guided CPR or standard CPR.

In the AMSA-CPR group, AMSA value suggests when the rescuer should deliver the defibrillation attempt; In the Standard-CPR group, the defibrillation is delivered based on the 2015 European Resuscitation Council (ERC) CPR guidelines.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

AMSA and Amiodarone Study in Cardiac Arrest

NCT04997980

Out-Of-Hospital Cardiac Arrest

COMPLETED

AED Use in Out-of-Hospital Cardiac Arrest: A New Algorithm Named "One Shock Per Minute"

NCT00139542

Heart Arrest Ventricular Fibrillation

COMPLETED PHASE3

To Determine Optimal Time for Delivering Electrical Shocks to Cardiac Arrest Patients

NCT01665755

Cardiac Event Sudden Cardiac Death Death +2 more

COMPLETED NA

Prophylactic Anti-aRrhythmic Therapy With Amiodarone in Critically Ill Patients Admitted for an Out-of-hospital Cardiac Arrest With Initial Shockable Rhythm

NCT06835491

Ventricular Arrhythmias and Cardiac Arrest

RECRUITING PHASE3

Prophylactic Amiodarone for Shockable Cardiac Arrest

NCT04845607

Cardiac Arrest Ventricular Arrythmia

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In the AMSA-CPR intervention, upon arrival of the advanced life support (ALS) rescue team at the cardiac arrest scene and application of the defibrillatory pads to the patient's chest and power on of the defibrillator with the real time AMSA analysis:

* If AMSA is ≥ 15.5 mV-Hz, an immediate defibrillation is attempted, followed by CPR
* If AMSA is \< 15.5 mV-Hz, defibrillation is not attempted and CPR is delivered
* During the 2-min cycle of CPR, AMSA is measured during pauses for ventilations (every 30 CC, approximately every 20/25 sec). If an AMSA value ≥ 15.5 mV-Hz is achieved prior to cycle completion, an immediate defibrillation is delivered (thus the defibrillation attempt is anticipated)

After completion of the first 2-min CPR cycle:

* If AMSA is ≤ 6.5 mV-Hz, the defibrillation is not attempted but CPR is continued
* If AMSA is \> 6.5 mV-Hz, an immediate defibrillation attempt is delivered, followed by CPR
* During the 2-min cycle of CPR, AMSA is measured during pauses for ventilations (every 30 CC, approximately every 20/25 sec). If an AMSA value ≥ 15.5 mV-Hz is achieved prior to cycle completion, an immediate defibrillation is delivered

After completion of the second 2-min CPR cycle and till the end of the resuscitative intervention:

• CPR is continued based on standard 2015 ERC guidelines (a defibrillation attempt every 2-min CPR cycles), except for the possibility to anticipate the defibrillation attempt if AMSA becomes ≥ 15.5 mV-Hz during the CPR cycle.

In the standard CPR intervention, upon arrival of the ALS team at the cardiac arrest scene, and application of the defibrillatory pads to the patient's chest and power on of the defibrillator:

• a defibrillation is immediately attempted and CPR is then started and continued for 2- min. Analysis of rhythm and subsequent defibrillation attempts are performed every 2-min CPR cycles.

In both study groups, the quality of CC and ventilation is monitored in real time thought the feedback integrated into the defibrillator.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Out-Of-Hospital Cardiac Arrest Ventricular Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AMSA-CPR

The professional rescuer decides to deliver the defibrillation attempt based on the AMSA value displayed in the defibrillator

Group Type EXPERIMENTAL

AMSA

Intervention Type DIAGNOSTIC_TEST

A non-invasive and real time VF (Amplitude Spectrum Area) AMSA analysis is performed during chest compression pauses for delivery of 2 ventilations, from the ECG acquired from the conventional defibrillatory pads

Defibrillation

Intervention Type PROCEDURE

delivery of the defibrillation is attempted to terminate VF either based on AMSA value (in the AMSA-CPR arm) or every 2-min CPR cycle as recommended by current guidelines (in the Standard-CPR arm)

CPR

Intervention Type PROCEDURE

chest compressions and ventilations at a rate of 30:2

Standard-CPR

The defibrillation is delivered based on the 2015 European Resuscitation Council CPR guidelines

Group Type ACTIVE_COMPARATOR

Defibrillation

Intervention Type PROCEDURE

delivery of the defibrillation is attempted to terminate VF either based on AMSA value (in the AMSA-CPR arm) or every 2-min CPR cycle as recommended by current guidelines (in the Standard-CPR arm)

CPR

Intervention Type PROCEDURE

chest compressions and ventilations at a rate of 30:2

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AMSA

A non-invasive and real time VF (Amplitude Spectrum Area) AMSA analysis is performed during chest compression pauses for delivery of 2 ventilations, from the ECG acquired from the conventional defibrillatory pads

Intervention Type DIAGNOSTIC_TEST

Defibrillation

delivery of the defibrillation is attempted to terminate VF either based on AMSA value (in the AMSA-CPR arm) or every 2-min CPR cycle as recommended by current guidelines (in the Standard-CPR arm)

Intervention Type PROCEDURE

CPR

chest compressions and ventilations at a rate of 30:2

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

VF waveform analysis electric countershock resuscitation maneuvres

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

All adult patients (age ≥ 18) suffering of out-of-hospital non traumatic cardiac arrest of presumably cardiac etiology with a presenting shockable rhythm requiring electrical defibrillation: Ventricular Fibrillation and pulseless Ventricular Tachycardia.

Exclusion Criteria

* age \< 18 years old
* pregnancy
* cardiac arrest with a non-shockable rhythm (pulseless electrical activity and asystole)
* a defibrillation delivered by an AED prior to ALS arrival
* cardiac arrest of traumatic origin
* non-cardiac cause of cardiac arrest
* presumable irreversible death or known terminal illness at the beginning of ALS
* clinical death
* participation in another clinical or device trial within the previous 30 days
* refused informed consent to the use of data.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No